Dr. Md Ibrahim is an Assistant Professor of Pharmacology, Cancer Biology, and Pharmaceutical Science at California Northstate University College of Pharmacy and founder of Oncovask Therapeutics LLC. His research focuses on overcoming cancer therapy resistance by targeting DNA damage repair pathways and replication stress responses.

He develops RNA-based therapeutics, including siRNA-loaded lipid nanoparticles, to silence undruggable DNA repair and checkpoint factors in glioblastoma, ovarian, and breast cancers. His work integrates proximity labeling (Split-TurboID), proteomics, and mechanistic studies of base excision repair and replication stress to restore sensitivity to PARP inhibitors, temozolomide, and alkylating agents.

Dr. Ibrahim also leads precision medicine efforts to repurpose FDA-approved drugs for rare cancers, investigates dormancy and metastasis in breast cancer using microfluidic tumor-on-chip models, and studies DNA repair dysfunction in neurodegenerative diseases such as ALS. His laboratory develops microfluidic and immunofluorescence-based diagnostic platforms for circulating tumor cell detection and precision monitoring.

In collaboration with experts in data science and materials science, he is building predictive oncology models that integrate omics and clinical datasets to personalize cancer treatment.